Indiana Basketball Fans Encouraged to Vote for Crimson Guard in Naismith Student Section of the Year Award
Jan. 12, 2012
BLOOMINGTON, Ind. - Indiana's Crimson Guard has been nominated as one of the top college basketball student sections in the country and is asking for fan support to help win the prestigious title. Hoosier fans will now have a say in determining the most deserving student section by voting for the Naismith Student Section of the Year Award.
By visiting Facebook.com/ILoveCollegeHoops, Indiana fans can vote for the Crimson Guard as the top student section in college basketball. The Naismith Student Section of the Year Award, which is presented through a partnership of The Collegiate Licensing Company (CLC), a division of IMG College, and the Atlanta Tipoff Club, administrators of the Naismith Awards, is dedicated to celebrating fans that love college hoops and provide support to their college basketball team with devotion and passion.
"There is no question in my mind that our students are the most loyal, dedicated, and supportive college basketball fans in the country," said IU head men's basketball coach Tom Crean. "I think you would be hard pressed to find a more deserving group for this honor."
Nearly 80 schools representing 21 conferences are vying for the title. The Big Ten and BIG EAST Conferences have the most schools participating followed closely by the ACC and Big 12. Participation also includes athletic conferences ranging from Conference USA and the Pac-12 to the Big Sky, the MAC, and Southland.
The Naismith Student Section of the Year Award will be determined through two rounds of public votes, combined with a scoring of finalists by the Naismith Awards Board of Selectors, which will review criteria such as the student section's name and attendance, as well as photos, video, and a write-up submitted by the nominating school. Complete details on the selection process can be found at Facebook.com/ILoveCollegeHoops.
If the Crimson Guard wins, it will donate the prize of $5,000 to Coaches vs. Cancer.
Check back soon